Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Peptide-based vaccination: where do we stand?

James N Francis1, Mark Larché

  • 1Department of Allergy and Clinical Immunology, Imperial College London, National Heart and Lung Institute, London, UK.

Current Opinion in Allergy and Clinical Immunology
|November 3, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ACLY inhibition promotes tumour immunity and suppresses liver cancer.

Nature·2025
Same author

Mapping the intersection of demographics, behavior, and government response to the COVID-19 pandemic: an observational cohort study.

BMC global and public health·2025
Same author

Thermostabilization of a model viral-vectored oral thin film vaccine.

International journal of pharmaceutics·2025
Same author

Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy.

Allergy·2023
Same author

Proceedings of the immune thrombocytopenia summit: new concepts in mechanisms, diagnosis, and management.

Research and practice in thrombosis and haemostasis·2023
Same author

Lasting Changes to Circulating Leukocytes in People with Mild SARS-CoV-2 Infections.

Viruses·2021
Same journal

Biosimilars in allergology: an outline in pediatric patients.

Current opinion in allergy and clinical immunology·2026
Same journal

The immunogenetic landscape of systemic lupus erythematosus.

Current opinion in allergy and clinical immunology·2026
Same journal

Circadian control of innate immunity: molecular mechanisms and implications for allergic disorders.

Current opinion in allergy and clinical immunology·2026
Same journal

Probiotics in allergic disease: from adjunct supplement to immune-modifying strategy (2026 update).

Current opinion in allergy and clinical immunology·2026
Same journal

Updates on drug-induced anaphylaxis in children.

Current opinion in allergy and clinical immunology·2026
Same journal

Beta-lactam de-labelling as a core antimicrobial stewardship strategy in the era of the antimicrobial resistance pandemic: a narrative review.

Current opinion in allergy and clinical immunology·2026
See all related articles

Peptide allergy vaccines offer a safer, more effective treatment for allergies by targeting T-cell responses. Advances in peptide design improve outcomes and reduce adverse reactions, enhancing allergy immunotherapy.

Area of Science:

  • Immunology
  • Allergy Research
  • Vaccine Development

Background:

  • Allergen-specific immunotherapy is the only causative allergy treatment.
  • Current immunotherapy can cause allergic reactions, including anaphylaxis.
  • Peptides are explored for allergy treatment due to their T-cell inhibitory potential without inducing anaphylaxis.

Purpose of the Study:

  • Evaluate peptides as a therapeutic approach for atopic allergic diseases.
  • Improve the safety and efficacy of allergy immunotherapy.

Main Methods:

  • Analyzing clinical trial data of peptide vaccination.
  • Investigating mechanisms of peptide vaccination, including T-cell hyporesponsiveness and regulatory T cell induction.
  • Designing novel peptide fragments with specific T-cell and B-cell epitopes.

Related Experiment Videos

Main Results:

  • Early peptide trials showed modest improvement but frequent adverse reactions.
  • Recent studies demonstrate improved clinical outcomes and safety.
  • Mechanisms involve allergen-specific hyporesponsiveness, regulatory T cells, and specific cytokine induction.
  • Novel peptide designs induce protective IgG responses and inhibitory antibodies.

Conclusions:

  • Manipulation of peptide epitopes enables rational design of safer and more effective allergy vaccines.
  • Further research into immunodominant epitopes can yield candidate peptides for vaccination.